 |
|
|
| |
Virologic Response Rates to All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir Regimens Are Similar in Patients With and Without Traditional Negative Predictive Factors in Phase 3 Clinical Trials
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Ira M. Jacobson,1 Paul Y. Kwo,2 Kris V. Kowdley,3 Jenny C. Yang,4 Yanni Zhu,4 Robert H. Hyland,4 Phillip S. Pang,4 John G. McHutchison,4 Mark S. Sulkowski,5 Nezam H. Afdhal6
1Sanford I. Weill Cornell Medical College, New York, NY; 2Indiana University School of Medicine, Indianapolis, IN; 3Virginia Mason Medical Center, Seattle, WA; 4Gilead Sciences, Inc., Foster City, CA; 5Johns Hopkins University, Lutherville, MD; 6Beth Israel Deaconess Medical Center, Boston, MA
|
| |
|
|
|
|
|
